bgb-3245
springworks therap,mapkure,Beigene
['bgb-3245', 'bgb-324']
bgb-3245 showed encouraging anti-tumor activity with a manageable safety profile in a phase 1a/1b trial for advanced or refractory tumors with a mutation in the mapk pathway. #aacr23 | 
Oncology news and insights from leading researchers and cancer centers.